This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ZEBOV

Merck & Co., Inc.

Drug Names(s): rVSV-EBOV Vaccine, BPSC1001, rVSVEBOV, V920, rVSV-ZEBOV-GP, V920 Ebola Vaccine

Description: NewLink is developing an Ebola vaccine.

Deal Structure: NewLink Genetics and Merck
In November 2014, Merck and NewLink Genetics entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV (Ebola) vaccine candidate.

Under the terms of the agreement, Merck will be granted the exclusive rights to the rVSV-EBOV vaccine candidate as well as any follow-on products. The vaccine candidate is under an exclusive licensing arrangement with a wholly-owned subsidiary of NewLink Genetics. Under these license arrangements, the PHAC retains non-commercial rights pertaining to the vaccine candidate.

Partners: NewLink Genetics Corporation


ZEBOV News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug